This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okunieff, P. Articles by Gerber, L. H. Search for Related Content PubMed PubMed Citation Articles by Okunieff, P. Articles by Gerber, L. H. Social Bookmarking                            What's this?

Pentoxifylline in the Treatment of Radiation-Induced Fibrosis

From the Department of Radiation Oncology, James P. Wilmot Cancer Center at the University of Rochester Medical Center, Rochester, NY; the Rehabilitation Medicine Department, Clinical Center, National Institutes of Health, and the Radiation Oncology Branch, National Cancer Institute, Bethesda; Maryland Regional Cancer Care-Waldorf, Waldorf, MD.

Address reprint requests to Paul Okunieff, MD, University of Rochester School of Medicine, 601 Elmwood Ave, Box 647, Rochester, NY 14642; e-mail: Paul_Okunieff{at}urmc.rochester.edu

PURPOSE: Fibrotic sequelae remain the most important dose-limiting toxicity of radiation therapy to soft tissue. Functionally, this is reflected in loss of range of motion and muscle strength and the development of limb edema and pain. Tumor necrosis factor alpha and fibroblast growth factor 2 (FGF2), which are abnormally elevated in irradiated tissues, may mediate radiation fibrovascular injury.

PATIENTS AND METHODS: In an open label drug trial, we studied the effects of pentoxifylline (400 mg orally tid for 8 weeks) on 30 patients who displayed late, radiation-induced fibrosis at 1 to 29 years posttreatment (40 to 84 Gy). The primary outcome measurement was change in physical impairments thought to be secondary to radiation, including active and passive range of motion (AROM and PROM), muscle strength, limb edema, and pain. Plasma levels of cytokines (tumor necrosis factor alpha and FGF2) also were measured. Twenty-seven patients completed baseline and 8-week assessments, and 24 patients completed baseline, 8-week, and 16-week assessments.

RESULTS: After 8 weeks of pentoxifylline intervention, 20 of 23 patients with impaired AROM and 19 of 22 with impaired PROM improved; 11 of 19 patients with muscle weakness showed improved motor strength; five of seven patients with edema had decreased limb girth; and nine of 20 patients had decreased pain. Pretreatment FGF2 levels dropped from an average of 44.9 pg/mL to 24.0 pg/mL after 8 weeks of treatment.

CONCLUSION: Patients receiving pentoxifylline demonstrated improved AROM, PROM, and muscle strength and decreased limb edema and pain. Reversal of these delayed radiation effects was associated with a decrease in circulating FGF2.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Okunieff, L. A. Kachnic, L. S. Constine, C. D. Fuller, L. E. Gaspar, D. F. Hayes, J. Hooks, C. Ling, F. L. Meyskens Jr., P. A. Philip, et al. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008 Clin. Cancer Res., September 15, 2009; 15(18): 5663 - 5670. [Abstract] [Full Text] [PDF]

				C. Bourgier, M.-C. Vozenin-Brotons, and R. Arriagada Enhanced Local Control by Radiation Boost in Breast Cancer: Back Side of the Coin? J. Clin. Oncol., December 20, 2007; 25(36): 5841 - 5843. [Full Text] [PDF]

				S. Delanian, R. Porcher, J. Rudant, and J.-L. Lefaix Kinetics of Response to Long-Term Treatment Combining Pentoxifylline and Tocopherol in Patients With Superficial Radiation-Induced Fibrosis J. Clin. Oncol., December 1, 2005; 23(34): 8570 - 8579. [Abstract] [Full Text] [PDF]